C-Stem biomimetic cell therapy manufacturing platform
preclinicalplatform · high
Enable scalable production of iPS-derived regenerative cell therapies using biomimetic encapsulation and 3D microtissue culture.
GMP-compliant encapsulation, microfluidics-assisted core-shell microcapsules, 3D micro-compartments, and stirred-tank bioreactor culture for hPSC expansion and differentiation.
Demonstrated scale-up to industrial-scale stirred tank bioreactors and use in preclinical production of Parkinson's disease neural microtissues.
A 3D micro-compartment system achieved 277-fold hPSC amplification in 6.5 days while maintaining pluripotency; the platform also supported scalable bioreactor production of dopaminergic neuron-containing neural microtissues for Parkinson's disease models.
hiPSC epithelial cortinoid mechanics research program
exploratoryresearch program · medium
Characterize how iPSC-derived epithelial cortinoids tolerate large deformations during growth and morphogenesis.
Inflation-deflation assays, high-resolution imaging, cytoskeletal analysis, and theoretical/computational modeling of fluid-filled iPSC epithelial shells.
Published study of reversible superdeformability mechanisms in hiPSC epithelial cortinoids.
Epithelial cortinoids were found to buffer mechanical load through reversible cytoskeletal tilt and bend instabilities, preserving epithelial hydraulic and topological integrity during large deformation.
Liver disease iPSC-derived cell therapy program
undiscloseddrug program · medium
Develop an iPSC-derived regenerative cell therapy program for liver disease.
iPS-derived cell therapy using TreeFrog's regenerative medicine and C-Stem/3D microtissue platform approach.
Listed in the company's pipeline as a liver disease program.
Parkinson's Disease iPSC-derived cell therapy program
preclinicaldrug program · high
Develop an iPSC-derived regenerative cell therapy for Parkinson's Disease using dopaminergic neuron-containing neural microtissues, with a stated goal of first-in-human testing by 2026.
Cell therapy using hiPSC-derived dopaminergic neuron-containing neural microtissues produced with high-throughput encapsulation and bioreactor culture in a 3D format.
Lead program described as on track for a first-in-human trial by 2026; preclinical Parkinson rat model data reported.
Bioreactor-produced cryopreserved 3D neural microtissues innervated host striatum and normalized rotational bias in a dose-dependent manner in a Parkinson rat model, with full behavioral recovery reported 16 weeks after transplantation.
zIncubascope incubator imaging platform
exploratoryresearch program · medium
Monitor assembly and growth of multicellular aggregates, microtissues, organoids, and encapsulated hiPSC systems over days to weeks.
Long-term quantitative imaging platform designed to operate inside an incubator, combined with a customized image-analysis pipeline.
Published demonstration of high-throughput monitoring of hiPSCs in spherical and tubular capsules and yeast cells in spherical capsules.
The platform provided quantitative insight into how confinement affects morphogenesis of self-organized biological systems.
